Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is June 02, 2024.
All times in Eastern Daylight Time.
-
June Joy at Juicy Stakes CasinoST JOHN’S, Antigua--(BUSINESS WIRE)--You know the drill. New month, same old Juicy Stakes Casino – bringing you a scorching set of specials with summer now firmly in sight. To mark the start of a v... more »
-
Bihar collabora con Bidgely per ridurre i furti di energia e le perdite di ricavi tramite l'analisi dei dati alimentata dall'IALOS ALTOS, Calif. e BANGALORE, India--(BUSINESS WIRE)--La società di partecipazione elettrica dello Stato del Bihar (BSPHCL) ha adottato l'intelligenza artificiale (IA) di Bidgely Energy Theft Solu... more »
-
Accutar Biotechnology、ASCO 2024にてER +/ HER2-乳がん患者におけるAC699単剤療法の第1相試験データを発表クランベリー、ニュージャージー州--(BUSINESS WIRE)--(ビジネスワイヤ) -- 人工知能(AI)対応創薬に焦点を当てたバイオテクノロジー企業のAccutar Biotechnology, Inc.は、ER陽性/HER2陰性の局所進行性または転移性乳がん患者を対象とした、現行のAC699単剤療法第1相試験データを発表しました。同データは、6月1日にイリノイ州シカゴで開催の米国臨... more »
-
Accutar Biotechnology在2024年ASCO年会上公布了在ER+/HER2-乳腺癌患者中开展AC699单一疗法一期试验的数据新泽西州克兰伯里--(BUSINESS WIRE)--(美国商业资讯)-- Accutar Biotechnology, Inc.是一家专注于人工智能支持的药物研发的生物科技公司,今天公布了该公司正在进行的在雌激素受体(ER)阳性/人表皮生长因子受体2阴性(HER2-)局部晚期或转移性乳腺癌患者中开展AC699单一疗法一期试验的数据。相关数据将于2024年6月1日在伊利诺伊州芝加哥举行的美国... more »
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven ... more »
-
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician... more »
-
RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States Dist... more »
-
MIAMI--(BUSINESS WIRE)--First Ascent Biomedical announced findings from ongoing clinical studies conducted in partnership with Florida International University, examining the company’s Functional P... more »
-
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluati... more »
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!OSAKA, Japan--(BUSINESS WIRE)--The city of Tondabayashi in Osaka is excited to announce a new inbound tour by "SABIWabisabi," aimed at revitalizing the local community. This exclusive tour combines... more »
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLCCHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ... more »
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein GroupTORONTO--(BUSINESS WIRE)--Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the Company”) today announced that it has closed its previously announ... more »
-
オムディアのRANベンダー・レポートでマべニアがトップに輝くテキサス州リチャードソン--(BUSINESS WIRE)--(ビジネスワイヤ) -- ネットワークの未来を構築するクラウドネイティブなネットワーク・インフラストラクチャ・プロバイダーであるマべニアは、オムディアによる最新の「市場環境:2024年RANベンダー」(Market Landscape: RAN Vendors 2024)レポートにおいて、「主要なチャレンジャー(Major cha... more »
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ CommunityNEW YORK--(BUSINESS WIRE)--Since 2019, Sally Hansen® has committed to partnering with GLAAD to support Pride and the organization’s mission to accelerate acceptance for the LGBTQ+ community. In the... more »
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol AmendmentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced ... more »